{"product_id":"bpc-157-tb-500-blend-20-mg","title":"BPC 157 + TB 500","description":"\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:0 0 .4em;font-family:inherit;\"\u003eWhat it is\u003c\/p\u003e\n\u003cp style=\"font-size:1.12em;line-height:1.7;margin:0 0 1em;\"\u003eTwo repair peptides in a single vial. They are studied for the same reason: \u003cstrong\u003ehelping the body repair damaged tissue\u003c\/strong\u003e —tendons, muscle, ligaments— faster than it would on its own.\u003c\/p\u003e\n\u003cp style=\"font-size:1.02em;line-height:1.7;margin:0 0 1.2em;color:#374151;\"\u003eBPC-157 is a laboratory copy of a small protein already present in human gastric juice. TB-500 is the active part of another protein, thymosin beta-4, which the body produces wherever there is a wound. Each one works in a different phase of repair, which is why they are combined.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat it is used for\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Tendon, ligament and muscle injuries that are slow to heal\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Recovery after intense exertion or surgery\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Digestive discomfort: the original research field of BPC-157\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Laboratory work on wound healing and new blood vessel formation\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it is used\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:12px;margin:0 0 1.4em;flex-wrap:wrap;\"\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eCycle\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003e4–6 weeks\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eBreak\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003e2–4 weeks\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eRoute\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eSubcutaneous\u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eThe vial comes as a powder. It is reconstituted with bacteriostatic water, swirled gently until dissolved —never shaken— and kept in the refrigerator between 2 and 8 °C. Each vial contains 20 mg in total: 10 mg of each peptide.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat has been observed\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;color:#6b7280;font-size:.95em;\"\u003eResults described in the published scientific literature. They are not directions for use or health recommendations.\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Preclinical studies describe faster healing of tendon, muscle, bone and intestine with BPC-157, including reattachment of tendon to bone after Achilles tendon detachment \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  BPC-157 has shown activity at very small doses and without demonstrable toxicity in the models reviewed \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[5]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Thymosin beta-4 accelerates skin wound closure: in the original model, 42% more re-epithelialization at 4 days and up to 61% at 7 days \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[7]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  It also reduces the number of myofibroblasts, which is associated with less scarring and less fibrosis \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[9]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Thymosin beta-4 reached human studies for skin wounds, corneal injuries and cardiac repair \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[9]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  The published pilot studies in people with BPC-157 reported no relevant adverse effects \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[4]\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it works\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eBPC-157 — cytoprotection and angiogenesis\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eA stable pentadecapeptide derived from a gastric protein. In preclinical models it promotes angiogenesis, modulates the nitric oxide pathway and shows broad cytoprotective effects in gastrointestinal, musculoskeletal and nervous tissue \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e. In tendon it promotes fibroblast outgrowth from the explant, their survival under stress and their migration, an effect attributed to activation of the FAK-paxillin pathway \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eTB-500 — cell migration and remodeling\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eThe active fraction of thymosin beta-4, the main actin-sequestering molecule in eukaryotic cells. It regulates the actin cytoskeleton and directs the migration of repair cells toward the injury, in addition to modulating the inflammatory response \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[6]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[9]\u003c\/sup\u003e. Its own actin-binding site is responsible for promoting angiogenesis \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[8]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eWhy they are combined\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eThey cover complementary phases of the same cascade: BPC-157 provides cytoprotection, trophic signaling and blood vessel formation; TB-500 provides cell migration and cytoskeletal remodeling. Together they span more stages of the repair process than either one alone.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eState of the evidence\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003ePreclinical: solid; clinical: limited.\u003c\/strong\u003e Reviews published in 2025 note that in humans there are only pilot studies with BPC-157 —intra-articular knee pain, interstitial cystitis and an intravenous safety and pharmacokinetics study— and that large, rigorous clinical trials are lacking; the long-term safety profile has not been established \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[4]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[5]\u003c\/sup\u003e. There are no published studies on the combined formulation: the available evidence is that of each component separately.\u003c\/p\u003e\n\n\u003cp style=\"margin:1.6em 0 0;padding:12px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e⚠️ Product intended exclusively for \u003cstrong\u003eresearch and laboratory use\u003c\/strong\u003e. Not for human or veterinary consumption.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eReferences\u003c\/p\u003e\n\u003col style=\"margin:0;padding-left:1.4em;font-size:.86em;color:#6b7280;line-height:1.7;\"\u003e\n  \u003cli\u003eChang CH, et al. \u003cem\u003eThe promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.\u003c\/em\u003e J Appl Physiol, 2011. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21030672\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 21030672\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eGwyer D, et al. \u003cem\u003eGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.\u003c\/em\u003e Cell Tissue Res, 2019. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30915550\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 30915550\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eKrivic A, et al. \u003cem\u003eAchilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation.\u003c\/em\u003e J Orthop Res, 2006. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16583442\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 16583442\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eVasireddi N, et al. \u003cem\u003eEmerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.\u003c\/em\u003e HSS J, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40756949\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40756949\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eMcGuire FP, et al. \u003cem\u003eRegeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.\u003c\/em\u003e Curr Rev Musculoskelet Med, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40789979\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40789979\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eGoldstein AL, et al. \u003cem\u003eThymosin beta4: actin-sequestering protein moonlights to repair injured tissues.\u003c\/em\u003e Trends Mol Med, 2005. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16099219\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 16099219\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eMalinda KM, et al. \u003cem\u003eThymosin beta4 accelerates wound healing.\u003c\/em\u003e J Invest Dermatol, 1999. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10469335\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 10469335\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePhilp D, et al. \u003cem\u003eThe actin binding site on thymosin beta4 promotes angiogenesis.\u003c\/em\u003e FASEB J, 2003. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14500546\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 14500546\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eGoldstein AL, et al. \u003cem\u003eThymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.\u003c\/em\u003e Expert Opin Biol Ther, 2012. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22074294\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 22074294\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"PeptidoBioGenetic","offers":[{"title":"10 mg + 10 mg","offer_id":55126439788873,"sku":"BB10","price":126.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1016\/7507\/3865\/files\/bpc-157-tb-500-20-mg-sin-fondo.png?v=1787687072","url":"https:\/\/www.peptidobiogenetic.com\/en-us\/products\/bpc-157-tb-500-blend-20-mg","provider":"PeptidoBioGenetic","version":"1.0","type":"link"}